ATRYS HEALTH SA
Type of ratings: Corporate
Rating value: BB
Outlook: Stable
License: EthiFinance Ratings
Solicited
EthiFinance Ratings affirms Atrys Group s "BB" rating, maintaining its Stable outlook. Atrys focuses its business on the health sector, ranging from the prevention of occupational risks to the integrated management of oncological disease (diagnosis and radiotherapy/immunotherapy). Currently, the group is in an expansion and consolidation through and outstanding inorganic and organic growth. In 2022, the group had (proforma and adjusted figures) a turnover of € 210.9m and EBITDA of € 47.2m (margin of 22.4%), also showing a NFD/EBITDA ratio of 4.8x. The group capitalization figure stood at € 377m in July 2023.
Ratings
Rating action: Affirmed
Action date: 31/07/2023
Date last rating: 31/07/2023
Date first rating: 08/07/2019
Methodology